Valneva 将来の成長

Future 基準チェック /46

Valnevaは、61.9%と18.1%でそれぞれ年率61.9%で利益と収益が成長すると予測される一方、EPSはgrowで48.7%年率。

主要情報

61.9%

収益成長率

48.75%

EPS成長率

Biotechs 収益成長	26.7%
収益成長率	18.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	16 May 2025

今後の成長に関する最新情報

Recent updates

Upcoming Lyme Vaccine Data Will Unlock Market Opportunities

May 14 Potential success of the Lyme disease vaccine could significantly boost future revenue and earnings through strategic regulatory filings and commercialization milestones.

Valneva SE (EPA:VLA) Analysts Just Slashed Next Year's Revenue Estimates By 13%

Feb 20

Valneva SE (EPA:VLA) Stock Catapults 35% Though Its Price And Business Still Lag The Industry

Feb 06

Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues

Nov 22

€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results

Nov 10

Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive

Sep 19

Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 17

Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 10

Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Apr 05

Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Mar 27

Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

Mar 15

News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Jan 06

Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Dec 13

業績と収益の成長予測

ENXTPA:VLA - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	312	53	-29	-13	4
12/31/2026	257	-22	-48	-36	6
12/31/2025	193	-84	-74	-65	6
3/31/2025	186	-80	-60	-47	N/A
12/31/2024	170	-12	-84	-67	N/A
9/30/2024	159	-7	-169	-143	N/A
6/30/2024	156	-32	-215	-204	N/A
3/31/2024	153	-24	-222	-207	N/A
12/31/2023	154	-101	-217	-203	N/A
9/30/2023	223	-113	-208	-193	N/A
6/30/2023	426	-7	-231	-211	N/A
3/31/2023	373	-135	-267	-243	N/A
12/31/2022	361	-143	-275	-245	N/A
9/30/2022	439	73	-195	-149	N/A
6/30/2022	304	-159	-177	-108	N/A
3/31/2022	347	-72	-83	2	N/A
12/31/2021	348	-73	-16	77	N/A
9/30/2021	121	-248	15	97	N/A
6/30/2021	110	-125	51	109	N/A
3/31/2021	98	-91	147	182	N/A
12/31/2020	110	-64	118	138	N/A
9/30/2020	104	-62	67	78	N/A
6/30/2020	120	-25	97	105	N/A
3/31/2020	127	-8	-7	3	N/A
12/31/2019	126	-2	-5	6	N/A
9/30/2019	116	4	0	10	N/A
6/30/2019	109	1	10	16	N/A
3/31/2019	116	7	14	17	N/A
12/31/2018	113	3	N/A	16	N/A
9/30/2018	107	-7	N/A	6	N/A
6/30/2018	110	-7	N/A	10	N/A
3/31/2018	108	-8	N/A	5	N/A
12/31/2017	105	-11	N/A	13	N/A
9/30/2017	103	-11	N/A	17	N/A
6/30/2017	100	-14	N/A	19	N/A
3/31/2017	102	-46	N/A	25	N/A
12/31/2016	98	-49	N/A	7	N/A
9/30/2016	93	-63	N/A	4	N/A
6/30/2016	96	-61	N/A	-5	N/A
3/31/2016	89	-35	N/A	-17	N/A
12/31/2015	83	-21	N/A	-20	N/A
9/30/2015	74	-16	N/A	-24	N/A
6/30/2015	65	-13	N/A	-19	N/A
3/31/2015	55	-9	N/A	-15	N/A
12/31/2014	42	-26	N/A	-15	N/A
9/30/2014	41	-21	N/A	-6	N/A
6/30/2014	43	-28	N/A	-21	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VLAは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1.6% ) よりも高い成長率であると考えられます。

収益対市場: VLA今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: VLA今後 3 年以内に収益を上げることが予想されます。

収益対市場: VLAの収益 ( 18.1% ) French市場 ( 5.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: VLAの収益 ( 18.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VLAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/05/16 23:03
終値	2025/05/16 00:00
収益	2025/03/31
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Valneva SE 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。24

アナリスト	機関
Stéphan Dubosq	Arkeon Finance
Jean-Jacques Le Fur	Bryan Garnier & Co
Bruno Bulic	Bryan Garnier & Co

Valneva 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Consensus EPS estimates upgraded to €0.006 loss

Consensus EPS estimates fall from profit to €0.012 loss, revenue upgraded

Forecast breakeven date pushed back to 2027

Consensus EPS estimates increase from loss to €0.08 profit

Price target decreased by 7.4% to €6.83

Recent updates

Upcoming Lyme Vaccine Data Will Unlock Market Opportunities

Valneva SE Provides Update on Recommended Use of IXCHIQ®? by Elderly Individuals in the United States

First quarter 2025 earnings released: €0.06 loss per share (vs €0.42 profit in 1Q 2024)

Valneva SE Provides Update Following European Medicines Agency Announcement on Use of Ixchiq®? in Elderly

Valneva SE Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

No longer forecast to breakeven

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Valneva SE Receives First Marketing Authorization for Single-Dose Vaccine IXCHIQ in A Chikungunya Endemic Country

Valneva SE and LimmaTech Biologics AG Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva SE's Chikungunya Vaccine IXCHIQ®? Now Authorized in EU for Adolescents Aged 12 and Above

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ, to UK MHRA

Valneva SE has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Consensus EPS estimates upgraded to €0.006 loss

Valneva SE Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine Ixchiq

Valneva SE (EPA:VLA) Analysts Just Slashed Next Year's Revenue Estimates By 13%

New major risk - Revenue and earnings growth

Consensus EPS estimates fall from profit to €0.012 loss, revenue upgraded

Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ

Valneva SE (EPA:VLA) Stock Catapults 35% Though Its Price And Business Still Lag The Industry

New major risk - Share price stability

Valneva SE Reports Positive Phase 2 Results in Children for Its Chikungunya Vaccine and Announces Phase 3 Dose Decision

Valneva Announces U.S. FDA Approval of Its Chikungunya Vaccine, Ixchiq

Forecast breakeven date pushed back to 2027

Valneva SE Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues

Consensus EPS estimates increase from loss to €0.08 profit

Price target decreased by 7.4% to €6.83

Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Forecast to breakeven in 2024

€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Financial position

Valneva SE to Report Nine Months, 2025 Results on Nov 13, 2025

Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive

Price target decreased by 11% to €7.68

New minor risk - Shareholder dilution

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Consensus EPS estimates fall from profit to €0.05 loss

Second quarter 2024 earnings released: €0.19 loss per share (vs €0.12 loss in 2Q 2023)

No longer forecast to breakeven

Consensus EPS estimates fall by 75%

Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings released: EPS: €0.42 (vs €0.13 loss in 1Q 2023)

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Full year 2023 earnings released: €0.73 loss per share (vs €1.24 loss in FY 2022)

New minor risk - Profitability

Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Consensus EPS estimates fall by 19%

Forecast to breakeven in 2024

Valneva Se Announces Earnings Guidance for 2024

Consensus EPS estimates upgraded to €0.05 loss

Consensus EPS estimates fall by 103%

Price target decreased by 8.6% to €9.17

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

No longer forecast to breakeven